Skip to main content
JNJ
NYSE Life Sciences

强生公司创新药品销售增长由Darzalex、Carvykti、Erleada、Rybrevant、Tremfya和Spravato推动

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
7
Price
$236.42
Mkt Cap
$573.154B
52W Low
$145.13
52W High
$251.71
Market data snapshot near publication time

summarizeSummary

此标题详细介绍了强生公司第一季度创新药品营业销售增长的关键驱动因素，特别提到了Darzalex、Carvykti、Erleada、Rybrevant/Lazcluze、Tremfya和Spravato。这是在昨天预期J&J第一季度销售额将更高的消息之后发布的。这些特定高性能药品的识别为公司的增长引擎提供了至关重要的洞察，确认了积极的销售轨迹，并提供了超出一般预期的细节。交易者将利用这些信息来评估J&J的产品线的实力及其驱动未来收入的能力。

在该公告发布时，JNJ的交易价格为$236.42，交易所为NYSE，所属行业为Life Sciences，市值约为$5731.5亿。 52周交易区间为$145.13至$251.71。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed JNJ - Latest Insights

JNJ
Apr 27, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Imaavy Secures FDA Priority Review for Rare Blood Disorder
Sentiment: Positive
View Wiseek Article
JNJ
Apr 24, 2026, 9:12 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J Acquires Atraverse Medical to Bolster Cardiac Device Portfolio
Sentiment: Positive
View Wiseek Article
JNJ
Apr 22, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
7
J&J Reports Strong Q1 Operational Sales Growth, Raises Dividend Amidst Talc Litigation Challenges and Increased Net Debt
Sentiment: Neutral
View Wiseek Article
JNJ
Apr 22, 2026, 10:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Nipocalimab-aahu Phase 3 Study Shows Sustained Improvements for Autoantibody Disease
Sentiment: Positive
View Wiseek Article
JNJ
Apr 17, 2026, 6:47 PM EDT
Source: Reuters
Importance Score:
8
Judge Rejects Bayer's Bid to Block J&J's Multibillion-Dollar Prostate Cancer Drug Claims
Sentiment: Positive
View Wiseek Article
JNJ
Apr 14, 2026, 4:07 PM EDT
Source: Wiseek News
Importance Score:
8
J&J Talc Bankruptcy Plan Voided by Court, Reopening Lawsuits; Q1 Revenue Hits $24B, Guidance Raised
Sentiment: Negative
View Wiseek Article
JNJ
Apr 14, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Johnson & Johnson Reports Strong Q1, Raises 2026 Guidance, and Increases Dividend for 64th Consecutive Year
Sentiment: Positive
View Wiseek Article
JNJ
Apr 14, 2026, 6:20 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Innovative Medicine Sales Growth Fueled by Darzalex, Carvykti, Erleada, Rybrevant, Tremfya, and Spravato
Sentiment: Positive
View Wiseek Article
JNJ
Apr 13, 2026, 12:44 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Johnson & Johnson Q1 Sales Expected Up, Profit Down Ahead of Earnings Report
Sentiment: Neutral
View Wiseek Article
JNJ
Mar 30, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
7
J&J Secures $500M R&D Pact for JNJ-4804, Reports 71% ORR for JNJ-1900 in NSCLC Trial
Sentiment: Positive
View Wiseek Article